|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
18 February 2013 |
|
Main ID: |
NCT01185405 |
|
Date of registration:
|
17/08/2010 |
|
Primary sponsor: |
|
|
Public title:
|
Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients
|
|
Scientific title:
|
Prediction and Adjustment of Voriconazole Plasma Level in Critically Ill Patients |
|
Date of first enrolment:
|
August 2010 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01185405 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Korea, Republic of
| | | | | | | |
|
Contacts
|
|
Name:
|
Sang-Ho Choi, MD |
|
Address:
|
|
|
Telephone:
|
82-2-3010-3304 |
|
Email:
|
sangho@amc.seoul.kr |
|
Affiliation:
|
|
|
|
Name:
|
Sang-Ho Choi, MD |
|
Address:
|
|
|
Telephone:
|
82-2-3010-3304 |
|
Email:
|
sangho@amc.seoul.kr |
|
Affiliation:
|
|
|
|
Name:
|
Sang-Ho Choi, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Asan Medical Center |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients who received voriconazole
Exclusion Criteria:
- Patients allergic to azole(s)
Age minimum:
16 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Invasive Fungal Infection
|
|
Intervention(s)
|
|
Other: Use of different strategy for voriconazole dosage adjustment
|
|
Primary Outcome(s)
|
|
Appropriateness of voriconazole trough level
[Time Frame: Day 3, day 5, day 10, and day 14]
|
|
Secondary Outcome(s)
|
|
Mortality
[Time Frame: 2 week, 4 week, 8 week, 12 week, and 24 week]
|
|
Voriconazole-related adverse event
[Time Frame: 1 week, 2 week]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|